Bolt Biotherapeutics, Inc. logo

Bolt Biotherapeutics, Inc. (BOLT) Q4 2024 Annual Earnings

BOLT·Reported March 24, 2025·Before market open

Bolt Biotherapeutics, Inc. reported Q4 2024 revenue of $10.0K, missed analyst consensus of $790.0K by $780.0K. Diluted EPS came in at $-7.60.

Revenue
$10.0Kmissed by $780.0K
Consensus: $790.0K
Diluted EPS
$-7.60met estimate
Consensus: $-7.60
SEC

SEC Filings

Earnings release8-K not filed yet
Annual report10-K · 0000950170-25-043873

Financial Snapshot

Trailing eight quarters through Q4 2024

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q4 2024 Earnings FAQ

Common questions about Bolt Biotherapeutics, Inc.'s Q4 2024 earnings report.

Bolt Biotherapeutics, Inc. (BOLT) reported Q4 2024 earnings on March 24, 2025 before market open.

Bolt Biotherapeutics, Inc. reported revenue of $10.0K and diluted EPS of $-7.60 for Q4 2024.

Revenue missed the consensus estimate of $790.0K by $780.0K. EPS beat the consensus estimate of $-7.60 by $0.00.

You can read the 10-K periodic report (0000950170-25-043873) directly on SEC EDGAR. The filing index links above go to sec.gov.